Evidence map›Paper›PMID 42151595›Full record

ArticleVirchows Archiv : an international journal of pathology2026

High‑Grade renal cell carcinoma with somatic BRCA2 mutation and biphasic morphology: an additional case expanding the morphological spectrum of an emerging RCC type.

Yingjing Wang, Xiaona Yin, Chengqing Xia, Ming Zhao

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yingjing WangNingbo Clinical Pathology Diagnosis Center, #685 Huancheng North Road, Zhejiang, 315000, China.
Xiaona YinNingbo Clinical Pathology Diagnosis Center, #685 Huancheng North Road, Zhejiang, 315000, China.
Chengqing XiaDepartment of Pathology, Chain Medical Labs, Hangzhou, 311100, China.
Ming ZhaoNingbo Clinical Pathology Diagnosis Center, #685 Huancheng North Road, Zhejiang, 315000, China. zhaomingpathol@163.com.ORCID http://orcid.org/0000-0001-5971-7303

Funding

Ningbo Municipal Key Medical Discipline (Western Medicine) Development Project 2026-A40Ningbo Top Medical and Health Research Program 2023010211Wu Jieping Medical Foundation Scientific Research Grant 320.6750.2025-24-2Zhejiang Provincial Medicine and Health Research Foundation WKJ-ZJ-26087
6 · The paper itself

Abstract

Renal cell carcinoma (RCC) associated with BRCA2 mutation is an extremely rare but increasingly recognized tumor type with characteristic but variable morphological features and aggressive behavior. We report a new case of high‑grade RCC harboring a somatic BRCA2 mutation in a 69‑year‑old male presenting with painless gross hematuria. The tumor exhibited a complex admixture of solid papillary/alveolar, cribriform, and tubulocystic architectures with prominent eosinophilic nucleoli. A biphasic pattern was observed, with central nests of more bland clear cells forming rosette‑like structures around hyaline basement membrane material, a finding reminiscent of TFEB‑altered RCC. Immunohistochemically, the tumor showed a nonspecific immunophenotype with expression of PAX8, CD10, and vimentin, while other RCC‑associated markers were negative. SMARCB1/INI1, SDHB, and FH expression were retained. Targeted next‑generation sequencing confirmed a somatic BRCA2 truncating mutation and absence of alterations in VHL, MET, TSC1/2/MTOR, SDHx, FH, or MiTF genes. A review of all five previously reported BRCA2‑associated RCCs revealed that all six reported cases (including ours) shared certain features: mixed papillary and solid architecture, high‑grade cytology with prominent nucleoli, and absence of other RCC‑defining molecular drivers. Our case not only reinforces the previously reported features but also expands the morphological spectrum of BRCA2‑associated RCC, providing further evidence that this may represent a distinct subtype of RCC.

Indexed as

Biomarkers, TumorBRCA2 ProteinCarcinoma, Renal CellKidney NeoplasmsMutationAgedHumansImmunohistochemistryMaleNeoplasm GradingBiomarkers, TumorBRCA2 ProteinBRCA2 protein, humanBRCA2 mutationHigh‑grade RCCRenal cell carcinomaSomatic mutationUnclassified RCC

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.